Common International Program:
Romania, the USA and the UK
World Health Organization, Geneva Switzerland
New Solution will be released and launched on the market to prevent coronavirus | COVID-19
Bucharest, Romania:
According to Dr. Alexandru Rafila, the President of the Society of Microbiology, Romania is already included on a countries’ short list where an anti-coronavirus new medicine will be tested.
Romania got such approval from the World Health Organization, in order to testing the anti-coronavirus drug.
Matei Bals Institute for Infectious Diseases Romania as the Excellence Unit Center for testing the clinic study of phase 3, for this medicine (commercial drug)
U.S Food and Drug Administration:
The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products etc.
Including also different patients from a seria of countries as well as different products , in order to influence FDA to release the commercial production and manufaturing, the American responsible authority, in the next few months.
Furthermore, by this fall Romania will accommodate and operate a suitable therapy. Not a vaccin, but a reliable efficient therapy delivered by an reputable American producer.
Romania is part of this complex American international study, in order to authorize of this drug. Other few countries are part of this work, too
As the statement of Prof. Dr. Streinu Cercel, a new testing procedure is ongoing in the UK and the results could be brought in Romania soon enough. It is a matter of a new vaccine being on testing lab procedures nowadays. The documentation almost ready to evaluating the volunteers.
Method: genetic engineering by the identification the virus structure able to produce antibodies.
Shortly Romania will receive, for validation, the protocol of proceeding and scientific collaboration.
Final step: the oppinion of the National Drug Agency
Both Dr. Rafila Alexandru and Prof Dr. Streinu Cercel were recommended, selected and approved to work in the mentioned program, by the American and British responsible entities and agencies, among others, as reputable and remarkable members of ZIVAC Romania Excellence Center, an exclusive unit to include various international rare experts. The center leadership is ensured by Dr. Leliana Parvulescu, President: http://zivac.ro/despre-zivac/
NAME: Remdesivir-most promising COVID-19 drug researchers ref.
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
The authors of a scientific lab research of all the potential therapeutics and vaccines for COVID-19 revealed that they believe the most effective therapeutic drugs will directly target the SARS-CoV-2 virus that causes COVID-19.
Other approaches: Antimicrobial Agents and Chemotherapy include blocking SARS-CoV-2 from entering cells, disrupting viral replication, antivirals, vaccines and suppressing overactive immune response.
SARS-CoV-2 is easily transmissible because Spike (S) proteins on the surface of the virus bind exceptionally efficiently to the angiotensin-converting enzyme 2 (ACE2) on the surfaces of human cells. One clinical study is already underway, testing if recombinant ACE2 can act as a decoy, binding the S proteins and preventing SARS-CoV-2 infecting cells in patients with severe COVID-19.
The most promising COVID-19 antiviral is remdesivir, which gets incorporated into viral RNA and prevents it being synthesised, halting viral replication. Remdesivir inhibited SARS-CoV-2 replication in laboratory studies and was tested in one patient with COVID-19 in US. The patient’s symptoms improved following intravenous remdesivir administration; however, more clinical data is required before the drug can be approved for use.
Tilarone is a broad-spectrum antiviral that may also be active against SARS-CoV-2. The synthetic small molecule is used in some countries, including Russia and neighbours, to treat several viruses, including acute respiratory viral infection, influenza and hepatitis. Other studies suggest tilarone may be active against Middle Eastern Respiratory Syndrome (MERS-CoV); however, the studies do not meet US Food and Drug Administration (FDA) standards for safety.
A further treatment option currently being explored, according to the experts, is the transfusion of blood from a recovered COVID-19 patient into someone with an active viral infection. This has primarily been used for patients in critical condition as it has a lack of high quality randomised clinical trial data to back up its efficacy. Several clinical trials investigating its effectiveness and safety against COVID-19 are now in progress.
The studies cited more than 15 vaccine candidates being developed globally, with various approaches to their design, and also suggest the expert opinion is that it will take approximately 12 to 18 months to get one to market. Daniel Niculae
